Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

Canaccord analyst Kyle Mikson lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $95 and keeps a Buy rating on the ...

Despite the weaker than expected results, Exact Sciences announced several pipeline advancements, including FDA approval for its next-generation Cologuard Plus test and promising data from its ...

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year ...

The Cologuard Plus test is now approved for adults ages 45 and older who are average risk for colorectal cancer (CRC).1 MADISON, Wis., September 16, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...